Please use this identifier to cite or link to this item:
Title: A Multicenter Randomized Trial of Continuous versus Intermittent β-Lactam Infusion in Severe Sepsis.
Austin Authors: Dulhunty, Joel M;Roberts, Jason A;Davis, Joshua S;Webb, Steven A R;Bellomo, Rinaldo ;Gomersall, Charles;Shirwadkar, Charudatt;Eastwood, Glenn M ;Myburgh, John;Paterson, David L;Starr, Therese;Paul, Sanjoy K;Lipman, Jeffrey
Affiliation: Pharmacy Department, Royal Brisbane and Women’s Hospital, Brisbane, Australia
Prince of Wales Hospital, Hong Kong
Chinese University of Hong Kong, Hong Kong
Department of Intensive Care, Austin Health, Heidelberg, Victoria, Australia
Australian and New Zealand Intensive Care Research Centre, Monash University, Melbourne, Australia
Department of Intensive Care, Royal Perth Hospital, Perth, Australia
School of Medicine and Pharmacology, University of Western Australia, Perth, Australia
Menzies School of Health Research, Charles Darwin University, Darwin, Australia
Department of Infectious Diseases, John Hunter Hospital, Newcastle, Australia
Department of Intensive Care Medicine, Royal Brisbane and Women’s Hospital, Brisbane, Australia
The Burns, Trauma & Critical Care Research Centre, The University of Queensland, Brisbane, Australia
Infectious Diseases Unit, Royal Brisbane and Women's Hospital, Brisbane, Australia
The University of Queensland Centre for Clinical Research, Brisbane, Australia
Critical Care and Trauma Division, The George Institute for Global Health, Sydney, Australia
St. George Clinical School, University of New South Wales, Sydney, Australia
Department of Intensive Care, Blacktown Hospital, Blacktown, Australia
Clinical Trials and Biostatistics Unit, QIMR Berghofer Medical Research Institute, Brisbane, Australia
Issue Date: 1-Dec-2015
Publication information: American Journal of Respiratory and Critical Care Medicine 2015; 192(11): 1298-305
Abstract: Continuous infusion of β-lactam antibiotics may improve outcomes because of time-dependent antibacterial activity compared with intermittent dosing. To evaluate the efficacy of continuous versus intermittent infusion in patients with severe sepsis. We conducted a randomized controlled trial in 25 intensive care units (ICUs). Participants commenced on piperacillin-tazobactam, ticarcillin-clavulanate, or meropenem were randomized to receive the prescribed antibiotic via continuous or 30-minute intermittent infusion for the remainder of the treatment course or until ICU discharge. The primary outcome was the number of alive ICU-free days at Day 28. Secondary outcomes were 90-day survival, clinical cure 14 days post antibiotic cessation, alive organ failure-free days at Day 14, and duration of bacteremia. We enrolled 432 eligible participants with a median age of 64 years and an Acute Physiology and Chronic Health Evaluation II score of 20. There was no difference in ICU-free days: 18 days (interquartile range, 2-24) and 20 days (interquartile range, 3-24) in the continuous and intermittent groups (P = 0.38). There was no difference in 90-day survival: 74.3% (156 of 210) and 72.5% (158 of 218); hazard ratio, 0.91 (95% confidence interval, 0.63-1.31; P = 0.61). Clinical cure was 52.4% (111 of 212) and 49.5% (109 of 220); odds ratio, 1.12 (95% confidence interval, 0.77-1.63; P = 0.56). There was no difference in organ failure-free days (6 d; P = 0.27) and duration of bacteremia (0 d; P = 0.24). In critically ill patients with severe sepsis, there was no difference in outcomes between β-lactam antibiotic administration by continuous and intermittent infusion. Australian New Zealand Clinical Trials Registry number (ACT RN12612000138886).
DOI: 10.1164/rccm.201505-0857OC
ORCID: 0000-0002-4524-0548
PubMed URL: 26200166
Type: Journal Article
Subjects: antibiotic
clinical outcome
intensive care
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Nov 28, 2022

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.